These include the use of Magnetic Resonance Imaging (MRI)-guided low-intensity focal ultrasound (LIFU) to temporarily open the blood–brain barrier (BBB) while the GBA1-PD patients are receiving an intravenous infusion of imiglucerase (CerezymeTM; Boston, MA, USA) [18], and the second involves a new small molecule, an allosteric activator of the glucocerebrosidase that stimulates/increases the activity of either wild-type or mutant enzymes (LTI-291, Bial Pharmaceuticals, Portugal; [19,20]). This evidence concerns the gene GBA1 and Parkinson disease.